High-content screening moves to the front of the line

Drug Discovery Today

Volumn 11, Issue 19-20, 2006, Pages 889-894

  Haney, Steven A ^a   LaPan, Peter ^a   Pan, Jing ^a   Zhang, Jing ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; G PROTEIN COUPLED RECEPTOR; PROTEIN INHIBITOR; REAGENT; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXO;

APOPTOSIS; CELL ASSAY; CELL MEMBRANE; CELL SCREENING; COMPUTER PROGRAM; CYTOLOGY; CYTOPLASM; DRUG SCREENING; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENOMICS; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; IMAGE ANALYSIS; MITOCHONDRIAL MEMBRANE; NEURITE; NICK END LABELING; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAINING; TRANSCRIPTION INITIATION;

BIOLOGICAL ASSAY; DRUG EVALUATION, PRECLINICAL; GENOMICS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSCOPY, FLUORESCENCE; RNA INTERFERENCE;

EID: 33748742351     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.08.015     Document Type: Review

References (54)

1. Bertelsen M., and Sanfridson A. Inflammatory pathway analysis using a high content screening platform. Assay Drug Dev. Technol. 3 (2005) 261-271
2. Borchert K.M., et al. High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay Drug Dev. Technol. 3 (2005) 133-141
3. Ghosh R.N., et al. A quantitative cell-based high-content screening assay for the epidermal growth factor receptor-specific activation of mitogen-activated protein kinase. Assay Drug Dev. Technol. 2 (2004) 473-481
4. Smolewski P., et al. Micronuclei assay by laser scanning cytometry. Cytometry 45 (2001) 19-26
5. Gurwitz D., and Haring R. Ligand-selective signaling and high-content screening for GPCR drugs. Drug Discov. Today 8 (2003) 1108-1109
6. Perfetto S.P., et al. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4 (2004) 648-655
7. Rausch O. Use of high-content analysis for compound screening and target selection. IDrugs 8 (2005) 573-577
8. Comley J. High content screening-Emerging importance of novel reagents/probes and pathway analysis. Drug Discovery World 6 (2005) 31-54
9. Lang P., et al. Cellular imaging in drug discovery. Nat. Rev. Drug Discov. 5 (2006) 343-356
10. Zhang J.-H., et al. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
11. Bunt G., and Wouters F.S. Visualization of molecular activities inside living cells with fluorescent labels. Int. Rev. Cytol. 237 (2004) 205-277
12. Bocker W., et al. Automated cell cycle analysis with fluorescence microscopy and image analysis. Phys. Med. Biol. 41 (1996) 523-537
13. Orimo A., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005) 335-348
14. Walsh N.C., et al. Rheumatic diseases: the effects of inflammation on bone. Immunol. Rev. 208 (2005) 228-251
15. Mrak R.E., and Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 26 (2005) 349-354
16. Russo C., et al. Molecular aspects of neurodegeneration in Alzheimer's disease. Funct. Neurol. 17 (2002) 65-70
17. Lapan, P. et al. Single cell analysis by high content screening improves the analysis of protein function using RNAi, as well as in unperturbed cells. in preparation
18. O'Neil N.J., et al. RNA-mediated interference as a tool for identifying drug targets. Am. J. Pharmacogenomics 1 (2001) 45-53
19. Haney, S.A. et al. RNAi in the drug discovery process, in RNA Interference Technology: From Basic Science to Drug Development, K. Appasani, Editor. 2005. Cambridge University Press, p. 331-346
20. Sachse C., and Echeverri C.J. Oncology studies using siRNA libraries: the dawn of RNAi-based genomics. Oncogene 23 (2004) 8384-8391
21. Willingham A.T., et al. RNAi and HTS: exploring cancer by systematic loss-of-function. Oncogene 23 (2004) 8392-8400
22. Echeverri C.J., and Perrimon N. High-throughput RNAi screening in cultured cells: a user's guide. Nat. Rev. Genet. 7 (2006) 373-384
23. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
24. Jackson A.L., and Linsley P.S. Noise amidst the silence: off-target effects of siRNAs?. Trends Genet. 20 (2004) 521-524
25. Birmingham A., et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3 (2006) 199-204
26. Fitzgerald K. RNAi versus small molecules: Different mechanisms and specificities can lead to different outcomes. Curr. Opin. Drug Discov. Devel. 8 (2005) 557-566
27. Huppi K., et al. Defining and Assaying RNAi in Mammalian Cells. Mol. Cell 17 (2005) 1-10
28. Jackson A.L., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21 (2003) 635-637
29. Haney S.A. RNAi and high-content screening in target identification and validation. IDrugs 8 (2005) 997-1001
30. Sachse C., et al. High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: functional genomics investigations of biological pathways. Methods Enzymol. 392 (2005) 242-277
31. Moffat J., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006) 1283-1298
32. Mousses S., et al. RNAi microarray analysis in cultured mammalian cells. Genome Res. 13 (2003) 2341-2347
33. Sonnichsen B., et al. Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature 434 (2005) 462-469
34. Kau T.R., et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4 (2003) 463-476
35. Perlman Z.E., et al. Automatic identification of subcellular phenotypes on human cell arrays. Science 306 (2004) 1194-1198
36. Kelloff G.J., et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 11 (2005) 7967-7985
37. Ross J.S., et al. Pharmacogenomics and clinical biomarkers in drug discovery and development. Am. J. Clin. Pathol. 124 (2005) S29-S41
38. Meng M.V., et al. Fine needle aspiration cytology of adult perineal rhabdomyosarcoma: a case report. Acta Cytol. 50 (2006) 88-92
39. Singhal S., et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 11 (2005) 3974-3986
40. Bruchez M.P. Turning all the lights on: quantum dots in cellular assays. Curr. Opin. Chem. Biol. 9 (2005) 533-537
41. Jaiswal J.K., and Simon S.M. Potentials and pitfalls of fluorescent quantum dots for biological imaging. Trends Cell Biol. 14 (2004) 497-504
42. Granas C., et al. High content screening for G protein-coupled receptors using cell-based protein translocation assays. Comb. Chem. High Throughput Screen. 8 (2005) 301-309
43. Wadsworth P., et al. Stable expression of fluorescently tagged proteins for studies of mitosis in mammalian cells. Nat. Methods 2 (2005) 981-987
44. Pelkmans L., et al. Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature 436 (2005) 78-86
45. Wilson C.J., et al. Identification of a Small Molecule That Induces Mitotic Arrest Using a Simplified High-Content Screening Assay and Data Analysis Method. J. Biomol. Screen. 11 (2006) 21-28
46. Tanaka M., et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 3 (2005) e128
47. Mayer T.U., et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286 (1999) 971-974
48. Giuliano K.A. High-content profiling of drug-drug interactions: cellular targets involved in the modulation of microtubule drug action by the antifungal ketoconazole. J. Biomol. Screen. 8 (2003) 125-135
49. Giuliano K.A., et al. High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of P53 activation in the cellular response to anticancer drugs. J. Biomol. Screen. 9 (2004) 557-568
50. Eggert U.S., et al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol. 2 (2004) e379
51. Zhou X., et al. A computerized cellular imaging system for high content analysis in Monastrol suppressor screens. J. Biomed. Inform. 39 (2005) 115-125
52. Keatley K.L. A review of US EPA and FDA requirements for electronic records, electronic signatures, and electronic submissions. Qual. Assur. 7 (1999) 77-89
53. Swedlow J.R., et al. Informatics and quantitative analysis in biological imaging. Science 300 (2003) 100-102
54. Brazma A., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29 (2001) 365-371